

FIG. 1

Patient sample nr.	Efficiency BCR-ABL	Efficiency GAPDH
1	87	74
2	78	61
3	71	66
4	73	55
5	67	55

FIG. 9






FIG.2

IgL κ intra-assay

C

IgL λ intra-assay

D




FIG.2 cont.

	IgL κ		IgL λ	
	CT _{max} ⁻ CT _{min} [*]	CV(CT) ⁺ CV(copy) ⁺	CT _{max} ⁻ CT _{min} [*]	CV(CT) ⁺ CV(copy) ⁺
Intra-assay	0,15	0,23% 3,0%	0,28	0,39% 4,9%
Intra-assay	0,37	0,62% 8,1%	0,25	0,37% 5,0%

FIG.3




FIG.4

Patient sample	IgL κ		IgL λ		$\frac{1 + E_{\text{IgL}\kappa}}{1 + E_{\text{IgL}\lambda}}$	K_{RS}^{\dagger}
	CT*	E †	CT*	E †		
BR0	21.0	79.4	21.7	76.8	1.014	1.42
BR18	17.2	86.6	18.8	75.2	1.065	-
BR37	22.2	84.2	20.8	75.7	1.048	1.84
BR42	18.7	90.4	17.9	84.4	1.033	1.41
BR46	17.1	82.8	16.4	77.9	1.028	1.42
BR52	21.9	88.7	17.9	85.8	1.015	-
Mean	85.4		79.3		1.034	1.52
Template	94.7		93.2		1.008	-
BR17	23.1	83.0	23.3	58.9	1.152	-

FIG.5




FIG.6

Sample	Real-time PCR % κ expression [†]	R.E.A.L. classification [*]	IHC clonality [*]	Flow Cytometry κ : λ expression [‡]
BR0	62 (52)	Lymphadenitis	poly	ND
BR1	(6)	NHL-CLL	IgL λ	1:99
BR2	(0.4)	NHL-DLBCL	IgL λ	3:97
BR4	(99)	NHL-CLL	IgL κ	95:5
BR5	(76)	NHL-Foll	IgL κ	65:35
BR6	(98)	NHL-DLBCL	IgL κ	ND
BR8	(8)	NHL-Foll	IgL λ	ND
BR11	(2)	NHL-Foll	IgL λ	32:68
BR13	(96)	NHL-CLL	IgL κ	96:4
BR17	6 (43)	NHL-Foll	IgL λ	32:68
BR18	16 (24)	NHL-Foll	IgL λ	ND
BR22	(83)	NHL-Foll	IgL κ	ND
BR23	(40)	T-cell lymphoma	-	ND
BR37	56 (63)	Lymphadenitis	poly	ND
BR42	62 (60)	Lymphadenitis	poly	ND
BR43	(68)	Lymphadenitis	poly	ND
BR46	62 (59)	Lymphadenitis	poly	46:54
BR48	(88)	NHL-Foll	IgL κ	ND
BR52	93 (89)	NHL-CLL	IgL κ	95:5

FIG. 7





FIG.8



BCR-ABL




FIG. 10

11/11




FIG.11